In a significant turn of events, Grifols, a Spanish healthcare firm operating a network of plasma donation clinics across Canada, has announced a temporary suspension of its collection services. This decision comes in light of the recent deaths of two donors and a government investigation into the practices at its facilities. The company informed Health Canada of its decision on Wednesday, coinciding with the agency’s issuance of a formal notice regarding non-compliance with blood safety regulations.
Investigation Prompted by Donor Deaths
The alarming incidents of donor distress occurred during plasma donation sessions in October 2025 and January 2026, both in Manitoba. While Health Canada has not disclosed the names of the deceased, sources indicate that one of the individuals was 22-year-old Rodiyat Alabede, an international student and aspiring social worker who passed away shortly after his plasma donation on 25 October.
Friends and advocates have raised serious concerns about the adequacy of screening procedures for donors. Kat Lanteigne, a campaigner for safe blood practices who is advocating for Alabede’s family, has stated, “They had staff taking plasma from donors who did not know how to extract plasma in a safe manner.” She emphasised that the failures identified in the clinics were significant enough to warrant further scrutiny into the circumstances surrounding these tragic events.
Autopsy Findings and Calls for Inquest
An autopsy revealed that Alabede succumbed to cardiac arrest shortly after his donation; however, Health Canada reported finding “no link” between his death and the plasma donation itself. Despite this, advocates are urging for a comprehensive inquest into Alabede’s death, citing “significant medical discrepancies” between his autopsy findings and Health Canada’s medical summary published in March.
Recent inspection reports from Health Canada have highlighted numerous deficiencies at Grifols clinics, including inadequate staff training, lapses in standard operating procedures, and poor record-keeping. Alarmingly, the reports indicate that staff failed to halt plasma collection when alarms were triggered, and the company’s reporting practices were labelled as “incomplete” and “inaccurate.”
The Plasma Donation Process and Its Importance
Plasma, the yellowish liquid component of blood, plays a crucial role in transporting blood cells and preventing excessive bleeding. It is vital for creating treatments for various medical conditions, including haemophilia, liver disease, and certain cancers. The process for donating plasma differs from that of blood donation; it typically involves a procedure called apheresis, which can take around 90 minutes, as opposed to the shorter duration of a standard blood draw.
In Canada, the regulation of paid plasma clinics varies by province. While British Columbia and Quebec have prohibited paid donations, Manitoba allows for such practices, which raises questions about the regulatory environment surrounding these clinics.
Grifols’ Response and Future Steps
In response to the unfolding situation, Grifols has stated that its decision to pause plasma collections is a “proactive and voluntary” measure aimed at addressing what it describes as “unfounded attention.” The company maintains that there is no direct connection between the donor deaths and the plasma donation process.
Health Canada has confirmed that deficiencies were found specifically at the Taylor Avenue clinic in Winnipeg and is working alongside Grifols to ensure the safety and integrity of operations. A spokesperson for the clinic assured the public that the quality and safety of Canada’s plasma and blood supply remains uncompromised.
Why it Matters
The tragic deaths of these young donors highlight significant concerns about the safety protocols and operational standards at plasma donation clinics. As the investigation unfolds, it raises critical questions regarding the regulation of paid plasma donation practices in Canada. Ensuring the safety of donors is paramount, and the outcomes of this inquiry could lead to stricter regulations and improved practices, ultimately safeguarding not just the health of donors but also the integrity of the healthcare system at large.
